|
Number of participants (n = M/F), % female.
|
114 (36/78), 68 %
|
92 (27/65), 72 %
|
107 (41/66), 61 %
|
|
Age: mean, median [range] (years):
|
37.5, 36 (18–63)
|
35.8, 36 (18–62)
|
38.2, 37 (18–68)
|
|
Time since first symptoms: mean, median [range] (years):
|
15.0, 16 (1–45)
|
17.8, 18 (1–51)
|
17.3, 13 (1–40)
|
|
Time interval between first symptoms and consultation with a specialist: mean, median [range] (months):
|
18.9, 4 (0.25–588)
|
28.4, 6 (0.25–360)
|
20.3, 11 (0.25–156)
|
|
Proportion of patients (%) having consulted the following physicians (mean number of visits per year):
| | | |
|
GP
|
92 % (3.4)
|
91 % (3.0)
|
70 % (3.9)
|
|
Allerist
|
87 % (2.0)
|
83 % (1.7)
|
70 % (1.4)
|
|
ENT specialist
|
27 % (2.3)
|
27 % (2.3)
|
15 % (1.7)
|
|
Dermatologist
|
24 % (1.6)
|
20 % (1.7)
|
8 % (2.6)
|
|
Pulmonologist
|
22 % (1.5)
|
32 % (1.6)
|
8 % (6.2)
|
|
Paediatrician
|
14 % (6.8)
|
9 % (1.0)
|
7 % (na)
|
|
Other
|
6 % (4.0)
|
2 % (1.5)
|
4 % (1.0)
|
|
Other self-reported allergies (% of patients):
| | | |
|
Grass pollen
|
79 %
|
67 %
|
67 %
|
|
Parietaria pollen
|
57 %
|
37 %
|
9 %
|
|
Cat dander
|
49 %
|
51 %
|
41 %
|
|
Dog dander
|
31 %
|
26 %
|
29 %
|
|
Olive pollen
|
27 %
|
41 %
|
35 %
|
|
Birch pollen
|
27 %
|
44 %
|
7 %
|
|
Moulds
|
24 %
|
29 %
|
35 %
|
|
Cypress pollen
|
21 %
|
48 %
|
9 %
|
|
None (i.e. HDMs only)
|
39 %
|
21 %
|
21 %
|
|
Proportion of patients (%) having consulted the following combinations of physicians:
| | | |
|
GP only
|
17 %
|
9 %
|
5 %
|
|
Allergist only
|
18 %
|
4 %
|
3 %
|
|
GP + allergist
|
33 %
|
25 %
|
31 %
|
|
GP + another specialist
|
7 %
|
7 %
|
5 %
|
|
GP + two specialists
|
11 %
|
29 %
|
26 %
|
|
GP + three or more specialists
|
4 %
|
22 %
|
28 %
|
|
Prevalence of co-morbidities (% of patients):
| | | |
|
Sinusitis
|
36 %
|
53 %
|
26 %
|
|
Otitis
|
13 %
|
18 %
|
9 %
|
|
Conjunctivitis
|
44 %
|
43 %
|
33 %
|
|
Headache
|
69 %
|
62 %
|
69 %
|
|
Time having used symptomatic medications (% of patients):
| | | |
|
Less than 2 years
|
7 %
|
3 %
|
3 %
|
|
2 to 5 years
|
35 %
|
28 %
|
21 %
|
|
6 to 10 years
|
22 %
|
39 %
|
30 %
|
|
11 to 20 years
|
21 %
|
23 %
|
27 %
|
|
More than 20 years
|
16 %
|
7 %
|
15 %
|
|
Degree of disease control (% of patients):
| | | |
|
Totally controlled
|
11 %
|
4 %
|
10 %
|
|
Well controlled
|
43 %
|
53 %
|
48 %
|
|
Moderately controlled
|
42 %
|
34 %
|
33 %
|
|
Poorly controlled
|
4 %
|
7 %
|
7 %
|
|
Not controlled at all
|
0 %
|
2 %
|
3 %
|
|
Proportion of patients (%) suffering from symptoms for more than 4 days in a week
|
70 %
|
58 %
|
54 %
|
|
Proportion of HDM-only allergic participants (%) with a peak in symptoms.
|
59 %
|
63 %
|
95 %
|
|
Proportion of patients (%) taking the following medications:
| | | |
|
Antihistamines
|
38 %
|
40 %
|
34 %
|
|
Nasal corticoids
|
7 %
|
12 %
|
10 %
|
|
Inhaled corticoids
|
3 %
|
3 %
|
9 %
|
|
Bronchodilators
|
7 %
|
12 %
|
15 %
|
|
Inhaled corticoids + bronchodilator
|
5 %
|
7 %
|
5 %
|
|
Oral or topical corticoids
|
12 %
|
3 %
|
4 %
|
|
Eye drops
|
4 %
|
6 %
|
4 %
|
|
Leukotriene receptor antagonists
|
2 %
|
4 %
|
3 %
|
